Objective We aimed at comparing clinical/immunological outcomes in human
immunodeficiency virus (HIV)-infected patients who were treated with CYP2B6-guided and …

Background Human immunodeficiency virus type 1 (HIV-1) infections with a plasma
efavirenz concentration of< 1,000 ng/mL appear to have a high risk for the emergence of …

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Interindividual variability in efavirenz
plasma concentrations is associated with CYP2B6 genetic polymorphisms.• Twenty‐nine …

The aim of this study was to assess the influence of host genetic variations and clinical
factors in relation to efavirenz level in HIV-1 infected Thai adults. A total of 100 HIV-infected …

Objectives Efavirenz is widely prescribed for HIV-1 infection. Three polymorphisms in
CYP2B6 define plasma efavirenz trough concentration strata that vary across an∼ 10-fold …

Efavirenz is a non-nucleoside reverse transcriptase inhibitor used as first-line therapy for the
treatment of HIV infection. Cytochrome P450 (CYP) CYP2B6 G516T (rs3745274) is a well …

Objectives Efavirenz is widely used in first-line antiretroviral therapy in sub-Saharan Africa.
However, exposure to efavirenz shows marked interindividual variability that is genetically …

Efavirenz is mainly metabolized by cytochrome P450 2B6 (CYP2B6). This study aimed to
examine the frequencies of CYP2B6 and the association between CYP2B6 polymorphisms …

Background. Efavirenz (EFV) is metabolized primarily by cytochrome P450 2B6 (CYP2B6),
and high plasma concentrations of the drug are associated with a G→ T polymorphism at …

Objectives Prior candidate gene studies have associated CYP2B6 516G→ T [rs3745274]
and 983T→ C [rs28399499] with increased plasma efavirenz exposure. We sought to …